We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-9.98%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.17B
AUM Growth
-$1.61B
Cap. Flow
-$473M
Cap. Flow %
-7.66%
Top 10 Hldgs %
32.27%
Holding
171
New
12
Increased
33
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$89.7M
2
PFE icon
Pfizer
PFE
+$66.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$65.8M
4
ARGX icon
argenx
ARGX
+$49.4M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$47.1M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$136M
2
BMY icon
Bristol-Myers Squibb
BMY
+$116M
3
HCA icon
HCA Healthcare
HCA
+$100M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$82.9M
5
SVA
Sinovac Biotech, Ltd
SVA
+$72.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
51
Theravance Biopharma
TBPH
$876M
$31.1M 0.5%
3,254,713
-2,719,822
-46% -$26.7M
SPRY icon
52
ARS Pharmaceuticals
SPRY
$539M
$30.7M 0.5%
8,740,887
– –
CMPX icon
53
Compass Therapeutics
CMPX
$358M
$29.7M 0.48%
21,642,975
– –
VRNA
54
DELISTED
Verona Pharma
VRNA
$28.4M 0.46%
5,694,841
– –
SCPH
55
DELISTED
scPharmaceuticals
SCPH
$27.2M 0.44%
4,797,148
– –
ACRS icon
56
Aclaris Therapeutics
ACRS
$722M
$27.2M 0.44%
1,579,900
+594,000
+60% +$8.1M
GHRS icon
57
GH Research
GHRS
$1.88B
$26.1M 0.42%
1,428,732
– –
VECT
58
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$25.1M 0.41%
5,330,704
+106,900
+2% +$559K
FUSN
59
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$25.1M 0.41%
3,224,770
– –
BIIB icon
60
Biogen
BIIB
$31.9B
$24.8M 0.4%
117,900
-112,300
-49% -$24.4M
KDNY
61
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$23.2M 0.38%
1,418,300
– –
IVVD icon
62
Invivyd
IVVD
$171M
$23.1M 0.37%
5,056,000
+72,500
+1% +$443K
PASG icon
63
Passage Bio
PASG
$14.9M
$22.7M 0.37%
366,600
+18,455
+5% +$1.52M
XENE icon
64
Xenon Pharmaceuticals
XENE
$6.23B
$21M 0.34%
686,000
+55,000
+9% +$1.65M
JNCE
65
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$19.4M 0.31%
2,859,900
– –
MREO
66
Mereo BioPharma
MREO
$50.2M
$19.3M 0.31%
+10,154,810
New +$13.1M
MRSN
67
DELISTED
Mersana Therapeutics
MRSN
$19.1M 0.31%
191,556
+76,002
+66% +$8.88M
GRCL
68
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$18.4M 0.3%
7,884,870
– –
IMA
69
ImageneBio Inc
IMA
$64.2M
$17.9M 0.29%
244,495
– –
VTYX
70
DELISTED
Ventyx Biosciences
VTYX
$17.5M 0.28%
1,289,280
– –
RXST icon
71
RxSight
RXST
$252M
$17.1M 0.28%
1,383,500
– –
GILD icon
72
Gilead Sciences
GILD
$166B
$17.1M 0.28%
287,600
– –
QURE icon
73
uniQure
QURE
$2.71B
$16.6M 0.27%
919,249
+333,675
+57% +$5.83M
MIST icon
74
Milestone Pharmaceuticals
MIST
$129M
$16.6M 0.27%
2,583,821
– –
RARE icon
75
Ultragenyx Pharmaceutical
RARE
$2.5B
$16.5M 0.27%
+227,600
New +$15.8M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2022 Portfolio in Review

As of Q1 2022, OrbiMed held 171 positions worth $6.17B, down 21% from $7.78B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $473M in Q1 2022, closing 28 positions and reducing 25 holdings. Its most notable exit was Merck, an estimated $136M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials.

Against the trend, OrbiMed opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $85.3M.

  • OrbiMed's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 719,034 shares worth $85.3M.
  • OrbiMed added most to Pfizer in Q1 2022, an estimated $66.9M increase.
  • OrbiMed's biggest Q1 2022 reduction was Bristol-Myers Squibb, cutting an estimated $116M.
  • OrbiMed fully exited Merck in Q1 2022, selling an estimated $136M.
  • OrbiMed's ten largest holdings make up 32% of its $6.17B portfolio in Q1 2022.
  • OrbiMed opened 12 new positions and closed 28 in Q1 2022.
  • OrbiMed's portfolio value fell 21% quarter-over-quarter to $6.17B.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.